Protara Therapeutics, Inc. filings document a Nasdaq-listed, Delaware clinical-stage biotechnology company developing TARA-002 for non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride for patients receiving parenteral support. Form 8-K disclosures include clinical-data updates, Regulation FD materials, financial results, investor presentations, and business updates related to the company's investigational programs.
The filing record also covers Protara's capital structure and governance, including common stock registered on The Nasdaq Global Market, public offering and underwriting agreements, warrant-related disclosures, and proxy materials for annual stockholder voting. Proxy filings describe board elections, executive compensation matters, equity plans, audit oversight, and other corporate-governance proposals.
Protara Therapeutics director Gregory Sargen received a grant of stock options covering 31,000 shares of common stock. The options have an exercise price of $3.94 per share, expire on June 14, 2036, and will vest in full on the first anniversary of the June 15, 2026 grant date, or upon a Change of Control, subject to his continued Board service. Following this award, the filing shows 31,000 derivative securities held directly.
Protara Therapeutics director Jane Huang received a stock option grant for 31,000 shares of common stock. The options have an exercise price of $3.94 per share and expire on June 14, 2036. The entire Annual Grant vests on the first anniversary of the June 15, 2026 grant date, subject to her continued board service, and also fully vests upon a Change of Control.
Protara Therapeutics director Roger Garceau received a grant of stock options for 31,000 shares of Common Stock. The options have an exercise price of $3.94 per share, expire on June 14, 2036, and vest in full on the first anniversary of the June 15, 2026 grant date or upon a Change of Control, subject to continued board service.
Protara Therapeutics director Barry P. Flannelly received a grant of stock options covering 31,000 shares of common stock. The options have an exercise price of $3.94 per share and expire on June 14, 2036.
According to the grant terms, the 31,000 options vest in full on the first anniversary of the June 15, 2026 grant date, as long as the director continues serving on the board, and they vest in full upon a Change of Control.
Protara Therapeutics director Luke M. Beshar received a grant of stock options covering 31,000 shares of common stock. These options have an exercise price of $3.94 per share and were awarded as compensation, not purchased in the open market.
The options were granted as an Annual Grant and will vest in full on the first anniversary of the grant date, as long as he continues serving on the board through that date. They will also vest in full upon a Change of Control, if that occurs earlier.
Protara Therapeutics, Inc. held its Annual Meeting of Stockholders, where all seven proposals received stockholder approval. Stockholders elected three Class III directors to serve until the 2029 annual meeting and ratified Ernst & Young LLP as independent auditor for the year ending December 31, 2026.
Stockholders approved, on an advisory basis, executive compensation and set the say‑on‑pay vote frequency at one year. They also approved an amendment to the 2024 Equity Incentive Plan and an amendment to increase authorized common shares from 100,000,000 to 200,000,000. An additional charter amendment allowing officer exculpation, as permitted by Delaware law, was also approved.
Protara Therapeutics, Inc. Chief Commercial Officer William Conkling reported a routine tax-related share disposition. On June 2, 2026, 6,008 shares of common stock were withheld by the company at $4.34 per share to cover income tax obligations from the vesting of Restricted Stock Unit Awards granted on June 2, 2025. After this withholding, Conkling directly holds 69,992 shares of Protara common stock. This transaction was not an open-market purchase or sale, but an administrative step tied to equity compensation.
Protara Therapeutics (TARA) has filed a prospectus supplement to sell up to $100,000,000 of common stock through an at-the-market sales agreement with TD Securities (USA) LLC (TD Cowen). Shares may be sold from time to time under the Sales Agreement, which permits sales on Nasdaq or by other methods permitted by law.
This offering is part of a $300,000,000 shelf registration. The prospectus supplement states last reported sale price of $5.27 per share on May 11, 2026 and uses proceeds to fund clinical development of TARA-002, IV Choline Chloride and other programs. The Sales Agreement allows TD Cowen to act as agent or principal, with compensation up to 3.0% of gross proceeds, and contains customary indemnification provisions.
Janus Henderson Group plc reports beneficial ownership of 5,207,011 shares of Protara Therapeutics, Inc. common stock, representing 9.6% of the class. The holdings are reported on behalf of multiple investment advisers that exercise shared voting and dispositive power for managed portfolios.
The filing notes that the Managed Portfolios generally exercise investment and voting discretion but do not have rights to receive dividends or sale proceeds; the Janus Henderson Biotech Innovation Master Fund Ltd. holds the right to receive dividends or proceeds for more than 5% of the class. The amendment is signed on 5/15/2026.